| Today’s Big NewsDec 6, 2024 |
|
Tuesday, December 10, 2024 | 12pm ET / 9am PT Mammalian synthetic biology has shown that key principles of biological regulation can be rewritten to control gene expression and produce complex, cellular behaviors. Recently, these core principles have now been applied at the protein level. Join us to learn about these latest approaches, and what the mean for cancer biology, immunology, and neuroscience. Sign up now!
|
|
| By Fraiser Kansteiner On Friday, Catalent and Novo Holdings said the European Commission granted “unconditional approval” to the companies’ pending $16.5 billion merger. With Europe’s blessing, Novo Holdings and Catalent now need to get a thumbs up from the U.S. Federal Trade Commission for their deal to pass muster. |
|
|
|
By Fraiser Kansteiner Resilience, which first emerged on the U.S. manufacturing scene in 2020, is laying off roughly 105 employees at its Alachua, Florida, facility. The CDMO originally got its hands on the facility—and some 300 new employees—through an acquisition in 2021. |
By Darren Incorvaia AmplifyBio is cutting costs, closing its R&D and characterization services site in South San Francisco and laying off employees in its Ohio-based preclinical CRO business, a company spokesperson confirmed to Fierce Biotech in an email. |
By Ayla Ellison,James Waldron This week on "The Top Line," we explore the biotech IPO market rebound and ask: Is the momentum here to stay? |
|
The right funding at the right time is crucial for life sciences companies that want to fuel innovation and scale operations. Download this free whitepaper to drive innovation, expand operations and lead your organization to further success.
|
|
By Conor Hale Donald Trump has named tech investor David Sacks to be “A.I. & Crypto Czar” as a newly created role in his administration next year, to help guide its approaches toward artificial intelligence. |
By Ben Adams Giving thanks, spending hours cooking a turkey and, as it turns out, a big helping of AbbVie were the biggest things in November as the Big Pharma big spender took the top two TV ad spending spots once again. |
By Zoey Becker The executives attended a dinner at the President-elect's Mar-a-Lago residence to discuss topics such as finding cures for cancer through private and public sector collaboration, Axios reports. |
By Nick Paul Taylor Duality Biologics has shared the first data from a phase 1/2a antibody-drug conjugate trial, giving an early look at how the BioNTech-partnered asset is shaping up against rival molecules in development at companies including Merck & Co. |
By Conor Hale Working with the real-world cancer data company COTA Healthcare, the former Fierce 15 winner put up its PreciseBreast test against Exact Sciences’ Oncotype DX. |
By Nick Paul Taylor LinkedIn likes have landed drugmakers in trouble once again. AstraZeneca—a repeat offender—and GSK were the subjects of the investigations under the U.K. marketing code, which found the companies broke the rules on promoting prescription medicines to the public. |
By Angus Liu After offloading a big chunk of their Japanese generics joint venture in 2020, Teva and Takeda have decided to divest the rest of the business so they can each focus on their innovative medicines. |
By Darren Incorvaia,Zoey Becker President-elect Donald Trump has chosen Stanford University’s Jay Bhattacharya, M.D., Ph.D., to serve as the director of the National Institutes of Health. Bhattacharya is a physician, professor and economic researcher known for co-authoring a controversial open letter in October 2020 that called for an end to pandemic lockdowns. |
By Kevin Dunleavy After slashing the U.S. prices of several of its insulin products by 75% at the start of 2024, Novo Nordisk is ending the year by announcing similar price reductions for most of its other insulins for patients who have diabetes. Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the company said. |
By Ben Adams Taiwan-headquartered PharmaEssentia has tapped Joseph Horvat as its new global chief commercial officer as it looks to boost its one approved drug and move more through its pipeline and into the market. |
Fierce podcastsDon’t miss an episode |
| This week on "The Top Line," we explore the biotech IPO market rebound and ask: Is the momentum here to stay? |
|
|---|
|
|
|
The European orphan drug market presents a significant opportunity, with forecasts predicting substantial growth in the coming years. Early access programs (EAPs) have emerged as a critical strategy for successfully launching rare disease therapies in this complex and diverse market. Access this whitepaper to learn more.
|
|
| WhitepaperWe interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| WhitepaperThis e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
